Linking MLL and the HGF-MET signaling pathway in liver cancer

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis

(2013) A Santoro et al.   BRITISH JOURNAL OF CANCER

HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma

(2013) Shugaku Takeda et al.   JOURNAL OF CLINICAL INVESTIGATION

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Loss of c-Met accelerates development of liver fibrosis in response to CCl4 exposure through deregulation of multiple molecular pathways

(2012) Jens U. Marquardt et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

The central role of the c-Met pathway in rebuilding the liver

(2012) S S Thorgeirsson   GUT

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

(2012) Armando Santoro et al.   LANCET ONCOLOGY

Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators

(2012) Akihiro Fujimoto et al.   NATURE GENETICS

Hepatocellular carcinoma with extrahepatic metastasis

(2011) Koji Uchino et al.   CANCER

The super elongation complex (SEC) and MLL in development and disease

(2011) E. Smith et al.   GENES & DEVELOPMENT

Hepatocyte growth factor/c-metsignaling is required for stem-cell-mediated liver regeneration in mice

(2011) Tsuyoshi Ishikawa et al.   HEPATOLOGY

Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): An emerging field for advanced technologies

(2011) Jens U. Marquardt et al.   JOURNAL OF HEPATOLOGY

MET signalling: principles and functions in development, organ regeneration and cancer

(2010) Livio Trusolino et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Therapeutic targeting of MLL

(2009) M. Liedtke et al.   BLOOD

Hepatocyte-specific c-Met Deletion Disrupts Redox Homeostasis and Sensitizes to Fas-mediated Apoptosis

(2008) Luis E. Gómez-Quiroz et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

(2008) Helena Linardou et al.   LANCET ONCOLOGY